• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Brain . Cerebrovascular Disease in Patients With COVID-19: Neuroimaging, Histological and Clinical Description

tetano

Editor, Senior Moderator
Brain


. 2020 Jul 9;awaa239.
doi: 10.1093/brain/awaa239. Online ahead of print.
Cerebrovascular Disease in Patients With COVID-19: Neuroimaging, Histological and Clinical Description


Francisco Hern?ndez-Fern?ndez[SUP] 1 [/SUP], Hern?n Sandoval Valencia[SUP] 2 [/SUP], Rosa Ang?lica Barbella-Aponte[SUP] 3 [/SUP], Rosa Collado-Jim?nez[SUP] 4 [/SUP], ?scar Ayo-Mart?n[SUP] 1 [/SUP], Cristina Barrena[SUP] 2 [/SUP], Juan David Molina-Nuevo[SUP] 4 [/SUP], Jorge Garc?a-Garc?a[SUP] 1 [/SUP], Elena Lozano-Seti?n[SUP] 4 [/SUP], Cristian Alcahut-Rodriguez[SUP] 1 [/SUP], ?lvaro Mart?nez-Mart?n[SUP] 1 [/SUP], Antonio S?nchez-L?pez[SUP] 5 [/SUP], Tom?s Segura[SUP] 1 [/SUP]



Affiliations

Abstract

Since the appearance of the first case of coronavirus disease 2019 (COVID-19) a pandemic has emerged affecting millions of people worldwide. Although the main clinical manifestations are respiratory, an increase in neurological conditions, specifically acute cerebrovascular disease, has been detected. We present cerebrovascular disease case incidence in hospitalized patients with SARS-CoV-2 infection. Patients were confirmed by microbiological/serological testing, or on chest CT semiology. Available data on comorbidity, laboratory parameters, treatment administered, neuroimaging, neuropathological studies and clinical evolution during hospitalization, measured by the modified Rankin scale, were analysed. A bivariate study was also designed to identify differences between ischaemic and haemorrhagic subtypes. A statistical model of binary logistic regression and sensitivity analysis was designed to study the influence of independent variables over prognosis. In our centre, there were 1683 admissions of patients with COVID-19 over 50 days, of which 23 (1.4%) developed cerebrovascular disease. Within this group of patients, cerebral and chest CT scans were performed in all cases, and MRI in six (26.1%). Histological samples were obtained in 6/23 cases (two brain biopsies, and four arterial thrombi). Seventeen patients were classified as cerebral ischaemia (73.9%, with two arterial dissections), five as intracerebral haemorrhage (21.7%), and one leukoencephalopathy of posterior reversible encephalopathy type. Haemorrhagic patients had higher ferritin levels at the time of stroke (1554.3 versus 519.2, P = 0.004). Ischaemic strokes were unexpectedly frequent in the vertebrobasilar territory (6/17, 35.3%). In the haemorrhagic group, a characteristic radiological pattern was identified showing subarachnoid haemorrhage, parieto-occipital leukoencephalopathy, microbleeds and single or multiple focal haematomas. Brain biopsies performed showed signs of thrombotic microangiopathy and endothelial injury, with no evidence of vasculitis or necrotizing encephalitis. The functional prognosis during the hospital period was unfavourable in 73.9% (17/23 modified Rankin scale 4-6), and age was the main predictive variable (odds ratio = 1.5; 95% confidence interval 1.012-2.225; P = 0.043). Our series shows cerebrovascular disease incidence of 1.4% in patients with COVID-19 with high morbidity and mortality. We describe pathological and radiological data consistent with thrombotic microangiopathy caused by endotheliopathy with a haemorrhagic predisposition.

Keywords: COVID-19; SARS-CoV-2; cerebrovascular disease; endotheliopathy; stroke.
 
Back
Top Bottom